Spine BioPharma announces $3 million investment by Pacira Biosciences
Spine BioPharma LLC announced a $3 million convertible note investment by Pacira Biosciences, with another $7 million in conditional milestones, according to a press release.
Spine BioPharma is a company focused on developing non-opiate, nonsurgical therapies for chronic low back pain caused by degenerative disc disease, according to release.
“We are delighted to welcome two investment partners that bring significant biopharma expertise, relationships, and scale to our ambitious mission of changing the lives of millions of patients suffering from chronic low back pain,” Marc Viscogliosi, CEO of Spine BioPharma, said in the release. “Remedisc represents a unique, best-in-class, first-in-class therapeutic that can provide a non-opiate, nonsurgical treatment option to these patients.”
Read more about